Eric Karas
Chief Commercial Officer at ARS Pharmaceuticals, Inc. (SPRY) since November 2022
Eric Karas has filed 13 insider reports with the SEC since November 2022, as chief Commercial Officer at ARS Pharmaceuticals, Inc. (SPRY). In the last 12 months Eric Karas sold $250K of stock on the open market. In the latest filing, on June 13, 2026, Eric Karas sold 25,000 shares of ARS Pharmaceuticals, Inc. (SPRY) for $250K at an average of $10.00.
- Filings
- 13
- Companies
- 1
- Bought on market
- None
- Sold on market
- $1.31M
Companies where Eric Karas is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Commercial Officersince November 2022 | 12,176 | $1.31M | $3.36 | Jun 13, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 12, 2026-$250KSPRYChief Commercial Officer Karas Eric exercised 25,000 shares at a strike of $1.50 and sold $250,000 worth of shares (25,000 units at $10.00) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 2, 2026SPRYSEC Form 4 filed by Chief Commercial Officer Karas EricForm 4Grant or award
- Jul 1, 2025-$255KSPRYChief Commercial Officer Karas Eric exercised 15,000 shares at a strike of $1.50 and sold $254,860 worth of shares (15,000 units at $16.99)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jun 18, 2025-$240KSPRYChief Commercial Officer Karas Eric exercised 15,000 shares at a strike of $1.50 and sold $240,000 worth of shares (15,000 units at $16.00)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 20, 2025-$140KSPRYChief Commercial Officer Karas Eric exercised 10,000 shares at a strike of $1.50 and sold $140,000 worth of shares (10,000 units at $14.00)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 2, 2025SPRYSEC Form 4 filed by Chief Commercial Officer Karas EricForm 4Grant or award
- Dec 4, 2024-$140KSPRYChief Commercial Officer Karas Eric exercised 10,000 shares at a strike of $1.50 and sold $140,423 worth of shares (10,000 units at $14.04)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Sep 18, 2024-$140KSPRYChief Commercial Officer Karas Eric exercised 10,000 shares at a strike of $1.50 and sold $140,000 worth of shares (10,000 units at $14.00)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Aug 19, 2024-$140KSPRYChief Commercial Officer Karas Eric exercised 10,000 shares at a strike of $1.50 and sold $140,000 worth of shares (10,000 units at $14.00)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 2, 2024SPRYSEC Form 4 filed by Karas EricForm 4Grant or award
- Jan 3, 2023SPRYSEC Form 4 filed by Karas EricForm 4Grant or award
- Nov 8, 2022SPRYSEC Form 4 filed by Karas EricForm 4Grant or award
- Nov 8, 2022SPRYEric Karas became an insiderForm 3New insider
Compare Eric Karas with
- Eric Karas vs John L Slebir1 shared
- Eric Karas vs Richard E Lowenthal1 shared
- Eric Karas vs Margaret Ekins Smith1 shared
- Eric Karas vs Donn Casale1 shared
- Eric Karas vs Rajeev Dadoo1 shared
- Eric Karas vs Pratik Shah1 shared
Other insiders at the same companies
- John L SlebirSPRY
- Richard E LowenthalSPRY
- Margaret Ekins SmithSPRY
- Donn CasaleSPRY
- Ra Capital Management, L.P.SPRY
- Rajeev DadooSPRY
- Michael KellySPRY
- Pratik ShahSPRY
- Brent L SaundersSPRY
- Phillip M SchneiderSPRY
- Saqib IslamSPRY
- Peter A. ThompsonSPRY
- Laura ShawverSPRY
- Alexander A FitzpatrickSPRY
- Kathleen D. ScottSPRY
- Brian DorseySPRY
Questions about Eric Karas
- What is Eric Karas's role at ARS Pharmaceuticals, Inc.?
- Eric Karas reports to the SEC as chief Commercial Officer at ARS Pharmaceuticals, Inc. (SPRY), according to the latest filing on June 13, 2026.
- How many shares does Eric Karas own?
- After the latest filing that states it, Eric Karas directly owned 12,176 shares of ARS Pharmaceuticals, Inc. (SPRY). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Eric Karas bought or sold stock recently?
- The most recent open-market sale was on June 12, 2026: sold 25,000 shares of ARS Pharmaceuticals, Inc. (SPRY) for $250K at an average of $10.00.
- How do I get alerts when Eric Karas files?
- Follow Eric Karas on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Eric Karas (SEC CIK 0001951287). Totals count each trade once, skipping amendments whose original is on file, from Nov 10, 2022 on. View on SEC EDGAR · Get this as JSON